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In Silico Toxicology Data Resources
to Support Read-Across and (Q)SAR
Gopal Pawar †, Judith C. Madden, David Ebbrell, James W. Firman and Mark T. D. Cronin*
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom
A plethora of databases exist online that can assist in in silico chemical or drug safety
assessment. However, a systematic review and grouping of databases, based on
purpose and information content, consolidated in a single source, has been lacking. To
resolve this issue, this review provides a comprehensive listing of the key in silico data
resources relevant to: chemical identity and properties, drug action, toxicology (including
nano-material toxicity), exposure, omics, pathways, Absorption, Distribution, Metabolism
and Elimination (ADME) properties, clinical trials, pharmacovigilance, patents-related
databases, biological (genes, enzymes, proteins, other macromolecules etc.) databases,
protein-protein interactions (PPIs), environmental exposure related, and finally databases
relating to animal alternatives in support of 3Rs policies. More than nine hundred
databases were identified and reviewed against criteria relating to accessibility, data
coverage, interoperability or application programming interface (API), appropriate
identifiers, types of in vitro, in vivo,-clinical or other data recorded and suitability for
modelling, read-across, or similarity searching. This review also specifically addresses
the need for solutions for mapping and integration of databases into a common platform
for better translatability of preclinical data to clinical data.
Keywords: databases, in silico, chemicals, drugs, safety assessment
INTRODUCTION
Chemical risk assessment refers to the quantification of any potential adverse effects to humans or
environmental species related to exposure to chemicals, drugs, pesticides, consumer products, or
any other substances. Traditionally, the assessment of chemicals, including pharmaceuticals, relied
on data from animal testing; however, there are many motivations to move to a society free of such
testing. In part, the new paradigm for safety assessment embraces the ethos of twenty-first century
Toxicology whereby every effort is made tomaximise the information that may be obtained without
animal testing (Embry et al., 2014). This information may include existing knowledge on the
chemical in question, or similar chemicals (the process of read-across), as well as in vitro and high
throughput determination relating to mechanisms of action and effects at the cellular or organ level
(Cronin et al., 2009; Kongsbak et al., 2014). Existing and experimental data are also supplemented
by predictions, which may relate to toxicity, mechanisms or exposure that are collectively termed
“in silico.” There is no formal definition for the process or practice of in silico chemical safety
assessment; however, it needs to encompass existing knowledge and outputs from predictions of
both hazard and exposure as a means of making a decision. There is also increasing interest in
making this type of information gathering and assessment more translational, to gain knowledge
from all sources to understand the effects on humans—patients in the case of pharmaceuticals—and
how that can be translated to mechanisms and assays etc.
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GRAPHICAL ABSTRACT | Word cloud of key words in the
databases reviewed.
There are various types of data that may be considered
in modern in silico chemical safety assessment. Historical, or
legacy, data from toxicological testing provide one of the most
important sources of information for modelling and read-
across. In theory, data should be available for all endpoints
that have been tested across a variety of guideline and non-
standard approaches. Such data may be either available openly
or be confidential business information and may encompass
toxicological and physico-chemical information. These data have
been the cornerstone of in silico modelling in the past and
remain essential for performing safety assessment of existing
chemicals. At the other end of the spectrum are upcoming
resources that capture mechanistic understanding of chemicals.
Such understanding has, in part at least, been facilitated by the
so-called “New Approach Methodologies” (NAMs) including in
vitro High-Throughput Screening (HTS) methods (bioactivity
or toxicity profiling bioassays) and omics data generated by
more specific genome sequencing, transcriptomics, proteomics,
and metabolomics studies (Hartung et al., 2017). These, and
other large data repositories, such as clinical effects and adverse
drug reactions are routinely referred to as being big data. The
term “big data” implies a huge volume of data collected from
multiple resources and characterised by their complexity and
heterogenous nature. Computational tools often manage big data
or algorithms that help to capture, store, search, and analyse the
data more rapidly.
Capturing a chemical’s physico-chemical properties,
bioactivity, and safety profiles or toxicity within databases
has become a necessary part of research across many industrial
sectors including pharmaceuticals, personal care products,
petro-chemicals, and biocides. As a result, in silico resources have
been reviewed and assessed previously by many researchers, as
indicated in Table 1, which identifies 48 of these recent reviews.
For example, Young (2002) reviewed web-based resources at the
US National Library of Medicine (NLM) including MEDLINE R©,
PUBMED R©, Gateway, Entrez, and TOXNET. As systems biology
emerged many gene expression repositories and software were
also developed (Anderle et al., 2003; Judson, 2010; Benigni et al.,
2013; Fostel et al., 2014). Efforts were not limited to only gene
or protein expression databases, but also included organ specific
toxicity databases. The review by Fotis et al. (2018) discussed
databases relating to genomics, proteomics, metabolomics,
multiomics whilst the review by Papadopoulos et al. (2016)
focused on such databases specifically relating to the kidney. In
relation to other major organs, liver, and heart-related toxicity
databases have been discussed by Luo et al. (2017) and Sato
et al. (2018), respectively. These diverse types of databases
have been further expanded or designed in such a way as to
enable interaction with other public resources so improving
accessibility for end users. Many resources have emerged that
try to link or integrate the chemistry-based databases with
bioactivity, pathways of toxicity, ADME, and omics data sets.
The chemistry-based databases on small molecules or new
compounds were discussed in detail in a number of reviews
(Jonsdottir et al., 2005; Williams, 2008; Hersey et al., 2015).
Some of the databases that allow for mining of the chemical
information (such as 2D, 3D structures, physico-chemical
properties etc.) are ChEMBL, ChEBI, PubChem, DrugBank,
ZINC, etc. In drug discovery, the number of databases for target
identification or prediction of activity, has grown tremendously
(Oprea and Tropsha, 2006; Loging et al., 2011; Chen and
Butte, 2016; Chen et al., 2016; Katsila et al., 2016; Cha et al.,
2018). Other databases containing information on proteins
associated with drug therapeutic effects, adverse drug reactions,
and ADME properties has facilitated systematic curation and
analysis of complex ligand-target data (Ji et al., 2003a). Some of
the ADME, potential drug-drug interaction (DDI) information
and pharmacogenomics-related databases have been cited in
a number of review articles (Ekins et al., 2005; Bauer-Mehren
et al., 2009; Ekins and Williams, 2010; Sim et al., 2011; Peach
et al., 2012; Wishart, 2014; Ayvaz et al., 2015; Zhang et al., 2015;
Przybylak et al., 2018). Fouretier et al. (2016) identified human
drug safety data resources, or pharmacovigilance databases,
specific to every country or subcontinent. The European Union’s
Innovative Medicines Initiative 2 Joint Undertaking (IMI
2) “Enhancing TRANslational SAFEty Assessment through
Integrative Knowledge Management (eTRANSAFE)” project is
developing an integrative data infrastructure to combine and
utilise data resources, hence has stimulated the work described in
this paper. The aim of eTRANSAFE is to drastically improve the
feasibility and reliability of translational safety assessment during
the drug development process using both publicly available
resources in addition to data provided by its partners to facilitate
acceptance by stakeholders, including regulatory agencies and
international organisations.
In spite of many previous reviews of data sources for specific
types of data (chemistry based, toxicology, omics, ADME etc.),
or those predominantly focussed on a specific type of data, no
review exists covering all data resources that may be required
for twenty-first century toxicology and translational sciences in
drug discovery. Moreover, many reviews have failed to address
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TABLE 1 | Previous review articles for identification of databases relevant to chemistry and toxicology.
Reference Categories covered No. of DBs covered Remarks
Alexander-Dann et al., 2018 Gene expression 12 Microarray software, database management systems
Ayvaz et al., 2015 Potential DDI information resources 14 Clinical, natural language corpora, pharmacovigilance data sources
Benigni et al., 2013 Chemical mutagenicity and
carcinogenecity
18 QSAR, Cluster of toxicity databases, risk assessment
Bianco et al., 2013 Genetic disease research databases 18 Sample sequence, gene expression and post-transcriptional regulation
Bower et al., 2017 Toxicity databases Toxicity data resources and format (ToxML) discussed
Cha et al., 2018 Drug repurposing databases 29 Drugs and disease (omics, genomics, transcriptomics, proteomics,
epigenetic) databases, omics tools also available
Chen et al., 2016 Drug-target interaction databases 15 Webserver databases and computational models included
Cheng et al., 2017 Drug Target interaction databases 28 3D structure, binding affinities Db, screening programs and data
repositories, Curated drug-target interactions
Cronin, 2005 Toxicology databases 26 Sources of chemical structures also described
Cronin, 2010 Toxicology databases 33 Data for QSAR modelling purposes
Ekins and Williams, 2010 ADME/Tox databases 13 Targeted data types required for ADME/Tox and PK databases
Ekins et al., 2005 Systems biology and ADMET 33 HT techniques, systems biology modelling and ADMET modelling included
Ekins et al., 2011 Tuberculosis (TB) databases 13 Computational databases, pathways, cheminformatics tools for TB
Fostel et al., 2014 Toxicogenomics 14 Relevant Databases and Consortia Supporting Systems Toxicology
Research
Fouretier et al., 2016 Pharmacovigilance (PV) 11 North American PV databases not covered
Fotis et al., 2018 Omic repositories 48 Omics and pathways, tools provided
González-Medina et al., 2017 Chemical biology databases 11 Online servers and tools for mining chemical and target spaces
Hersey et al., 2015 Chemical databases 10 Bioactivity, Patents, drugs and target, available compound and other
Ji et al., 2003b Proteins associated with drug
therapeutic effects, ADR and ADME
44 Targets related databases and their websites
Jonsdottir et al., 2005 Prediction methods, cheminformatics
DBs
23 General, screening compounds, medicinal agents, physicochemical and
ADMET properties
Judson, 2010 Toxicology databases 15 in vitro, in vivo toxicity and ontology-based databases
Kiyosawa et al., 2006 Microarray databases 7 Large scale toxicogenomics databases
Koutsoukas et al., 2011 Bioactivity and target predictions 20 Bioactivity and target-based databases, WS for target prediction of small
molecules
Katsila et al., 2016 Drug target identification databases 19 Human metabolome, pathway analysis, chemogenomic data, drug-target,
protein, disease specific target DB, pharmacogenomic, toxicogenomic,
target-toxin, protein expression, therapeutic target
Loging et al., 2011 Drug repurposing 11 Public resources
Luo et al., 2017 DILI databases 11 Liver specific injury and broader drug databases
Madden, 2013 Toxicity, reactivity, chemical property
and structural data
30 Assessment of quality data provided (Klimisch score criteria)
Madden et al., 2019 PBPK and ADME Resources ∼100 Resources to predict external exposure, physico-chemical properties,
ADME properties, physiological/anatomical parameters and model
structures for specific organs, PBPK modelling softwares, similar chemicals
Nicola et al., 2012 Medicinal chemistry databases 12 Databases of binding and bioactivity data for small molecules
Opassi et al., 2018 Chemical-Biology databases 28 Virtually accessible chemical spaces, biology databases
Oprea and Tropsha, 2006 Target, chemical and bioactivity 24 Integration of the databases
Papadopoulos et al., 2016 Omics databases on kidney disease 18 General omics and kidney specific databases
Peach et al., 2012 Metabolism related content 11 Software for metabolism predictions
Polen et al., 2008 Online drug databases 14 Drug databases for infectious disease therapies
Rana et al., 2012 Receptor and binding databases 26 Websites for computational, GPCR specific and nuclear receptors
Rigden et al., 2016 Molecular biology databases 157 Nucleic acids, genetic basis of cancer, patented drugs, their side effects,
withdrawn drugs, and potential drug targets
Sato et al., 2018 hERG inhibitors, cardiotoxicity 4 hERG inhibition by small molecules
Sim et al., 2011 Pharmacogenetics 7 Pharmacogenomics, CYP, NAT, Transporters, UGT, ADME Dbs
(Continued)
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TABLE 1 | Continued
Reference Categories covered No. of Dbs covered Remarks
Smalter Hall et al., 2013 Chemical and biological databases 20 Protein interaction, pathways, drug discovery, mathematical models
databases, data formats for proteomics and genomics and cheminformatics
provided.
Toropov et al., 2014 Drug toxicity databases 27 Software for QSAR analysis of toxic endpoints also given
Williams, 2008 Chemical property databases 15 Publicly available databases
Wishart, 2014 Drug metabolism research 13 Online databases and prediction software for drug metabolism
Wooden et al., 2017 Big data analysis resources 18 Big data for gastro intestinal and liver diseases
Young, 2002 Genetic toxicology web resources 13 EPA, FDA, US NLM toxicity databases discussed
Zou et al., 2015 Biological databases for human
research
>100 DNA, RNA, Proteins, expressions, pathways, disease, ontology and
literature-based databases listed
Zhang et al., 2015 Pharmacogenomics 8 Web resources
the importance of the full identification, mapping and integration
of chemical and biological spaces. Thus, the aim of this study was
to provide a comprehensive and consolidated list of in silico data
resources for chemical safety assessment. This review aimed to
encompass all data resources including those based on chemistry,
pharmacological space, genomics, and adverse events, as well as
those relevant to toxicology and human effects or clinical safety
studies. The databases were assessed in groups based on their
purpose and information content; data relating to each resource
was recorded and summarised. It is intended that this review will
provide a valuable starting point for researchers wishing to gain
knowledge about a chemical substance and its exposure/effect in
preclinical and clinical studies.
METHODS
Initially, the different types of databases to be reviewed
were established. The categories chosen for investigation
were chemistry-based databases containing information on:
toxicology (preclinical studies for chemicals and drugs),
genes or enzymes, pathways or AOP-related, omics, protein-
protein interactions, ADME, drug discovery, clinical trials,
pharmacovigilance, patent-based, environmental chemical
exposure, nanomaterial toxicity and animal alternatives, or 3Rs
related databases. These categories were utilised to facilitate the
searching and grouping/clustering of databases. An iterative
process was followed to identify the multiple independent,
disparate databases by searching for specific category-based
databases in published review papers (Table 1), regulatory-based
websites (US FDA, EPA etc.), chemical/pharmaceutical company
websites and some of the specific resources on databases such as
Toxnet1, Pathguide2, Fair sharing3, VLS3D4, Wikipedia5, Oxford
Journal’s biological databases6, and AltTox.org7 etc.
1https://toxnet.nlm.nih.gov/
2http://pathguide.org/
3https://fairsharing.org/databases/
4http://www.vls3d.com/
5https://en.wikipedia.org/wiki/List_of_biological_databases
6https://www.oxfordjournals.org/nar/database/a/
7http://alttox.org/resource-center/databases/ etc
The criteria by which the databases were assessed were
established and are summarised in Table 2; the criteria stipulate
both essential and desirable features. Each database was
screened using these criteria and only those meeting minimum
requirements are included within this review. The most
important criterion on which to select a database was its ease
of accessibility. The databases could be considered as “open”
(free to accesss or use, right to share and re-use) or “partially
open” (where only partial metadata are available to access or
download or not intended for commercial use). Some of the
databases for which the URL links are retired were removed
from the list. The availability of information on the type of
Application Programming Interface (API) or the programming
codes used to develop the databases was also considered as
a criterion in selecting the databases. Other essential criteria
include- appropriate chemical identifiers (such as SMILES,
InChIs etc.), readily converted ontologies and the relevance
of the endpoint(s). The desirable attributes included access
to the metadata, study protocols, information on data quality
assessment, ease of navigation, and other database statistics
relating to the frequency of updates and number of compounds
or drugs reported. Additional criteria related to the nature of the
information provided or the potential use of the database and
covers the type of data recorded (in vitro/ in vivo/ biomarkers/
omics/ clinical data etc.). The type of data incorporated in the
database was limited not only to experimental data (in vitro, in
vivo) but also included predicted data, quantitative structure-
activity relationship (QSAR) models, similarity searching for
chemicals or genes and read-across methods.
The list of more than 900 databases is provided in Table 3
and other detailed information of each database is compiled
in an Excel spreadsheet (Supplementary Information). The
information included: the name of the database; the owner of
the database; any licensing requirements or restrictions on use;
the URL or other information on database location; access rights
(e.g., registration requirement, free access, potential to download
all data etc.); endpoints covered; number and type of compounds
included; granularity of data (e.g., test results, dose-response
data, experimental conditions etc.) and details on data quality
assurance (e.g., details of curation and assignment of quality
score such as Klimisch scores) where applicable. Klimisch scores
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TABLE 2 | Considerations for characterising the databases.
ESSENTIALS
Accessibility (open access; registration; license required)
Interoperability (linkage via API or importable)
Acceptable ontology and units (or readily converted)
Appropriate identifiers used (e.g., InChI)
Relevance of endpoint (s) project: physico-chemical properties; ADME (including
metabolite data); pharmacological activity; toxicity; clinical trial data; adverse
events reports
DESIRABLES
Access to metadata
Information provided on study protocols/statistics
Data quality assessment and accuracy of information
Ease of use/navigation
Appropriate classification codes (e.g., therapeutic group classification)
Currency of information (historical; frequency of updates); size of resource
(amount of data / level of detail)
NATURE OF INFORMATION/POTENTIAL USE
Type of data recorded (in vitro/in vivo/biomarker/omics/targets) etc.
Relevance to overall aim of any project (e.g., extrapolation from preclinical to
clinical)
Experimental vs. predicted values
Insights into mechanisms of action/elicitation of molecular initiating event
Suitability for modelling, read-across, or similarity searching
(Klimisch et al., 1997) are assigned to toxicological or physico-
chemical data to assess their adequacy, relevance and reliability.
The scores are as follows: 1 = reliable without restrictions; 2 =
reliable with restrictions; 3 = not reliable 4 = not assignable.
These scores are based on criteria such as whether the study
was conducted under Good Laboratory Practice (GLP) and if
key information on test substances, experimental conditions and
statistical evaluation was stated.
RESULTS
Based on the criteria established herein for selecting databases,
a comprehensive list of more than 900 databases was compiled
(Table 3) and consolidated. The types and relative proportion of
databases identified are summarised in Figure 1. The key features
of the databases within each of the 13 groups identified are
summarised below.
I. Chemistry Databases
Eighty chemistry databases were identified which relate to
resources containing a large library of diverse chemicals
or compounds with additional information such as name,
molecular formula, structure (2D/3D), key identifiers (CAS
Registry Number, IUPAC name, InChI, SMILES), physico-
chemical properties, and associations with their bioactivities8.
Generally, such databases enable users to perform chemical
similarity searches based on different fingerprinting methods
such as MACCs, Atom pairs, and Topological Torsion
Fingerprints etc. However, despite potentially high numbers
8References are included in Supplementary Data Sheet S1, section I.
of compounds, many of these databases are very sparsely
populated particularly with regard to high quality toxicity data.
Such data resources do provide a useful and usable gateway to
multiple databases such as ChEMBL, KEGG, GeneTox, Daily
Med etc.
The applicability, efficiency, and diversity of any database
depends on the extent of coverage of chemical space.
Within the chemical databases, PubChem (Butkiewicz
et al., 2017) includes the highest number of compounds (97
million compounds, 238 million substances, 264 million
bioactivities, 3 million patents, and 633 data sources) in
comparison to ChemSpider (Pence and Williams, 2010) (68
million chemical structures, 252 data sources), and ChEMBL
(Gaulton et al., 2017) (1.8 million compounds and 1.1 million
assays). However, the uniqueness of these chemistry-based
databases lies in their associations with bioactivities. For
example, ChEMBL provides data on bioactive molecules
(drug-like properties) and links chemical, bioactivity,
and genomic data. ChemSpider provides information on
physical properties, biological activities (where available),
interactive spectra, the name of chemical suppliers, and other
miscellaneous information.
The chemistry-based databases also possess additional tools
such as drawing tools, the capability to search for similar
structures (both 2-D and 3-D) using similarity scorings,
facilities for structure clustering, identifier exchange services,
classification browsers, facilities enabling bulk download etc.
For the purposes of virtual screening of compounds, building
blocks or scaffolds/fragments, many databases were identified
such as ZINC-15 (Sterling and Irwin, 2015), ChemSpace9,
eMolecules10, Generated DataBase (GDB-DB) (Ruddigkeit
et al., 2013), Biovia Screening Compounds Directory (SCD)11,
Probes and Drug portal etc. (Skuta et al., 2017). Zinc-15
covers over 230 million ready-to-dock compounds in 3D-
formats and 750million purchasable compounds for screening
purposes. In comparison to Zinc-15, Chemspace covers 100
million, eMolecules 1.5 million and GDB-DB 26.4 million
structures for small organic molecules. Biovia SCD contains
9.7 million unique “drug-like” chemicals for HTS and lists
over 21 million individual products with prices and supplier
ordering information.
The Probes and Drugs portal is a partially open resource of
bioactive compounds (probes, drugs, kinase inhibitors etc.) for
commercial screening purposes. It contains 48 compound sets,
46,401 compounds, 34,887 standardised compounds, 18,612
scaffolds, 6,206 targets, 498,201 bioactivities, 2,455 pathways,
4,174 target/pathway classes, 483 structural alerts, and 2,791
matched structural alerts. Other DBs such as ChemDB (Chen
et al., 2007) and OCHEM (Sushko et al., 2011, 2012) could
be useful for providing a modeling framework to perform
QSPR/QSAR studies online. ChemDB contains nearly 5
million small molecules and includes data on predicted
or experimentally determined physicochemical properties
9https://chem-space.com/
10https://www.emolecules.com/
11http://accelrys.com/
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TABLE 3 | Complete listing of all databases identified in this study grouped according to content (URL links available on-line).
Chemistry (80) Toxicological (57) ADME (38)
AuroraFineChem DOCK Blaster OCHEM ACToR Lhasa Carcinogenecity Db ADME-AP
Biovia ACD Danish QSAR Db OSDDChem Acute Tox LIVERTOX ADME Db
Biovia SCD Elsevier Reaxys Organic syntheses Akos Toxicity LTKB ADMET SAR
BioByte eChemPortal PubChem Biovia Toxicity MDL-Toxicity / met ADMET Lab
CAS SciFinder e-Drug3D PPD CPDB NCI-60 (DTP) ADMENET
CCID eMolecules PCDDB COSMOS NCTRIcdb Akos Metabolites
Cfam eQuilibrator Probes & drugs portal CTD Open TG-GATEs AMED Cardiotoxicity
ChemDB FDB-17 Probe Miner CEBS OEHHA Chemical Bioprint
CCDS FilTer BaSe R & D Chemicals ChemTunes pCEC BBB
Chemistry Dashboard FDA UNII SDBS Coptis Tox PROTOX CYP DI table
ChEMBL GDB Db Spresi CCRIS PAFA CYP P450 Inhibitors
ChemAgora GOSTAR MedChem Sigma-Aldrich CREST Db RTECS DIDB
ChemSpider HDAC Inhibitors Base Symmetry @Otterbein DSSTox Repdose EDETOX Db
Chemfinder IUPAC-NIST Solubility SPIM diXa Super Toxic e-PK gene
ChEBI IUCLID SIDS DevTox SAR Genetox Db ECVAM KinParDB
Common chemistry JRC QSAR Model Db Wikipedia Drug Matrix SAR Carcinogenicity FINDbase
Chemspace LipidBank WebReactions DART Toxline HIA
Chembiobase Lipidomics Gateway ZINC15 eTox ToxDB IDAAPM
Chemexper LookChem EADB Toxygates IIMDB
CCCBDB Massbank EDKB Toxbank Liceptor
ChEBI MolPort ETOXNET Tox 21 Microsomal Stability
CERES METLIN EASIS Toxcast METRABASE
Chem synthesis mzCloud EDCs DataBank ToxRefDB OI-DDI
COD MERCK INDEX Online ECVAM Geno T3DB pKa DB
CheLIST MMsINC FeDTex TerraTox PACT-F
ChemIDplus NCI-OPEN Db Gene-Tox Vitic Nexus PK/DB
Chemistry Guide NICEATM Ref Chem Lists HESS Pharmapendium
ChemACX NMRShiftDB ISSTOX PDSP Ki
ChemSink NIST Chemical Kinetics ITER Tox-database.net
ChemSub Online NIST Chemistry Web Book JECDB TransportDB
Common Compound Library NIST, Atomic Spectra Leadscope TCDB
TR MetaDrug
ADME Drug discovery (157) Clinical trials/ PV
(116)
TP-Search Allosteric database Cyclonet Ensembl Protists Metabase PoSSuM ATC-DDD
TTD ASDCD CPRG ExCAPE-DB Metacore PathogenBox AACT DB
TRANSFORMER AffinDB ChEMBL-NTD e-Drug3D MOSAIC RepurposeDB ALFRED
UCSF ph’genetics APD CancerDRD EMBASE MEDock Rx Nav AFND
UCSF-FDA
TransPortal
AutoBind Cell Image Library ELDD MICAD Sc-PDB AutDB
WOMBAT-PK ARDB CCGD FDA NDC MTB SuperDRUG 2.0 BfArM
(UAW-Datenbank)
XMetDb Abiofilm Chemical Probes FDA Orange Book mSignatureDB Super Target BmDR
Autism Chromosome
Rearrangement
CARD FaCD Online mutLBSgeneDB SM2miR Bioportal
ADHDgene cBioPortal Flow Repository MK4MDD SuperPred/target/toxic BRCA Exchange
Allergome CCDB GenomeCRISPR MethyCancer SuperPain BioLINCC
AutismKB CS-DEGs GOLD NPASS Swiss Bioisotere BioProject
Biovia MDDR DART Gene DB NCATS SIMAP Colorectal Cancer Atlas
(Continued)
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TABLE 3 | Continued
ADME Drug discovery (157) Clinical trials/ PV
(116)
Biovia CMC DPD GDKD NLDB Swiss Dock CKB
Binding DB Drugs@FDA GLIDA NCCN Swiss Sidechain CancerPPD
Binding MOAD DT-Web GDSC NCGC SFARI Gene Clinical Codes
BioByte DTOME HMDC NeuroMorpho.Org TDR Targets CVRG
BioLiP DRH HIV-1 Human Int NIF TBDTBD C-Path
Brenda DTC HIV Drug
Resistance
NPACT THPdb CPRD
Biomodels DrugEBIlity Human TFDB NCG6.0 TCM-ID CPIC
BioMart DrugMiner IntSide Neuron DB TPDB ClinVar
BCNTB Bioinformatics DCDB ICGC OBO Foundry TTD ClinicalTrials.gov
BARD Drug Bank Integrity Oral Cancer Gene
Db
TAG CDSCO
BIG Data Centre DSigDB IQ Consortium Open Target TCMID COSMIC
BDGene DrugCentral Influenza Research OpenPHACTS TADB 2.0 CTRP
CLiBE D3R KDBI Orphanet TissGDB ChemDB HIV
CCD vault DBAASP KinMutBase PICKLES VKCDB DSUR
CTD2 Drug2gene KLIFS PhID VIPR Daily Med
CancerResource DGIdb Kinase SARfari PLDB WHO Drug Info DISQOVER
canSAR DNASU LigDig PHAROS TADB 2.0 DAAB
CARLSBAD DriverDBv2 LiverAtlas PharmGKB Decipher
CREDO Disease Meth MetaADEDB PROMISCUOUS Drug Information Portal
CAMPR3 EuPathDB Malaria Data PDBbind-CN DB
Biological databases (268)
Drug Trials Snapshots MedLine SPC/PIL AbMiner Candidate Cancer
Gene
Eye Gene
Drug Safety Labeling Changes Micromedex STRIDE (STARR) AntiJen CarpeDB EuMMCR
Drug consumption Db Medsafe (SMARS) Safeguard -DSRU AlzhCPI CRISPRlnc Ebola
Disease Ontology MedWatch Sundhedsstryrelsen Allen BrainMapAtlas CirGRDB ExplorEnz
Drug Product Db MeSH STEP Antibody Registry CCDS ERGR
ENCePP NDF-RT SUSARs ABCdb DisProt EPDnew
EPOCRATES NAPDI T R ‘s Cortellis AHTPDB DDBJ Fraggle
EudraVigilance ORDO TGA (DAEN) ADPriboDB dbPTM Fusion GDB
EAHD -CF-DB Ontobee TCIA AntigenDB Directory of CYP P450 GenBank/WGS
EudraCT Open FDA Trialtrove Aaindex dbSNP GlycoEpitope
EU CTR Opportu Inf and TB Ther D TERIS AVPdb dbGaP GLASS
EORTC Clinical Trials Db OSB UBERON Addgene dbVar GEO
EFO Pharmacy One Resource USP-NF Alliance of Genome Resources dbNP GPCRdb
First Databank PSUR UMLS AlloMAPS DBTSS Genome 3D
FDA’s IND/NDA/ANDA Protect ADR DB VarCards Array Map DIDA GTEx portal
FAERS PMDA VAERS AH-DB DDMGD GENT
GUDID PBRER Vigibase ACLAME dbDEMC GO
GePaRD PANDRUGS WHO ICTRP ADHDgene DEPOD Gencode
GHR Physio Para for Older
Adults
WITHDRAWN bioDBnet D2P2 GlyTouCan
Gold Standard Drug DB PEPID Yellow card BUSCO ExoCarta GtRNAdb
HC-SC (MedEffect) PharmaVar Brain Transcriptome ENCODE Genome properties
HPO Pharmacopoeias Bio Wiki ExAC GENATLAS
HEROD PILLBOX Broad Bioimage Enzyme Portal GermOnline
ICD-10 PDBSE BioMuta EMDB GPMdb
(Continued)
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TABLE 3 | Continued
Biological databases (268)
iSAEC PhysioBank BDB Eidogen-Sertanty GlycoNAVI
IB PPMI CPDB ECO GeneSeeker
IDA PDX-Finder CASBAH Ensembl GenomeRNAi
JH APX Guide PedAM CAMEO ENZYME HAMAP
LOINC RxNorm CanEvolve EGA HGNC
Lareb SIDER 4.1 CHOPIN Enzyme Portal Human Protein Atlas
MedDRA SNOMED-CT CanGem ENA HPRD
Medicines Complete Swiss Var CATH-Plus EMPIAR Human Genome Project
HERvD Kinweb MINAS PDBTM RMDB tRFdb
HORDE KIDFamMap MIPModDB PsychEncode RAID THPdb
HAGR LABOME Modomics Pro kinase resource SAGD The Antibody registry
HEMD LGICdb Metal PDB ProtChemSI Stanford Tissue
Microarray
Telomerase
HPM Lipidomics Gateway NRR PHI SCDE The MaxQuant
HIV Molecular Immu DB LncRNADisease v2.0 NPD Peptides Guide Super Hapten UbiProt
HomloGene LOCATE NextProt PDB SysteMHC Atlas UniProtKB
hPSCreg MGC NURSA PRIDE SNPeffect UniProbe DB
HGVD MITOMAP NC-IUBMB PROXiMATE Si Records ValidatorDB
Histome miRWalk NPIDB PHOSIDA Superfamily ViralZone
HEDD MGnify NIH 3D Print
Exchange
PSCDB Swiss Lipids VariO
HGVS MHCBN NODE Proteome Isoelectric Point SSBD VDJdb
H-InvDB MitoProteome Nextprot PED SBCDDB WebTB.org
iPTMnet MEROPS Noncode Plasmid starBase Wnt Db
IEDB MultitaskProtDB NATsDB Probe SelenoDB 1000,000 Genome
Project
IUPHAR MatrixDB O-GlycBase Platinum SBKB 3did
IMGT MPSTRUC OrthoDB PeroxisomeDB SWISS-Model 5S RNA
InterPro MiRBase Over gene Db PDBsum Syn Sys Net
iProClass MRMAssayDB ORDB Pfam SynLethDB
ImmPort Metagene Onco Db HCC Polbase Sc-PDB
InSiGHT variant Db MitoMiner Organelle DB PolymiRTS STRENDA
IntEnz Morphinome Organelle Genome ProtoNet SDAP
IPD MeDReaders Open SNP PrimerBank SYFPEITHI
IMGT/GENE-DB MSDD OGEE ProtCID STRING
IMGT/mAb-DB Meth HC PANTHER PPT-DB SM2miR
IMOTA miRandola PRINTS Rhea tRNAdb
Interferome MetalPDB PSP RoadMapepigenomics TSGene
IDR MicrobiomeDB PRO RBPDB topPTM
JGI Genome portal Mitocheck Phospho-ELM RNAcentral Tp53
JGA Membranome Phospho 3D RegPhos TCDB
Kinase.com MetaBase Plasma Proteome REPAIRtoire TubercuList
Protein-protein
interactions (54)
Omics (60) Pathways (38)
APID MIPS Angiogenes Incardiome Kb AOP-KB TIGER
BioGRID MENTHA Array Express IPD Aging Chart Transpath
BCL2DB MATADOR Array Track KUPKB BioCyc TriForC
CancerNet MINT BiGG LOMA Biocarta TCSBN
(Continued)
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TABLE 3 | Continued
Protein-protein
interactions (54)
Omics (60) Pathways (38)
ComPPI ORTI BioSample Metabolomics workbench DIMEdb UCSD-Nature
Signaling Gateway
CAZY PSMDB Biostudies MetaCore Effectopedia Wiki Pathways
Complex Portal PPI AD 2.0 BML-NMR MutAIT Gene Network XTalkDB
CORUM PiSITE BMRDB MitoProteome HumanCyc
Differential Net ProtinDB BioPlex MSigDB iPAVS
DynaSIN ProtChemSI Biosystems MobiDB KEGG
DIP PINT BioXpress MBROLE 2.0 MetaCyc
DOMMINO PIMADb C-MAP Nephroseq MetaboLights
gpDB PSILO ccmGDB NCI-60 (DTP) MetaMapTox
GWIDD PIPs CEGA OMIM Molsign
HINT Peptide Atlas Cancer Genomic
Hub
Omics DI MMMP
HIP SCOPPI CKDdb PACdb Nrf2ome
HPRD SKEMPI CTRP PRIDE PID
H-InvDB SNAPPIView Depmap PharmacoDB PDID
HCSGD TRIP 2.0 Disnor READDB Pathway Commons
HitPredict UniHI DrugSig RefSeq PCD
Innatedb Wiki-Pi DGVa Rfam Path Card
IMEx 3did DRUGSURV RGED pathDIP
INstruct DB 2P2Idb DisGeNet SignaLink2 PathwaysWeb
IRView DGIdb Signor PathArt
IntAct Expression Atlas TB DRM Db Path Base
I2D FiehnLib Db TCGA REACTOME
IIIDB GMD TCAG Mal Card
iMOTdb Gene Card Uni Carb-DB yAPOPTOSIS
iRefWeb HKUPP UPdb SMPDB
KBDOCK HMA STITCH
miRTarBase HMDB 4.0 TiPs
Patents (9) Environmental
exposure (30)
Animal alternative methods
(39)
Nanomaterials toxicity (22)
DWPI ATSDR ALTBIB OMIA CBNI
EPO ASTDR MRLs AWIC RGD caNanoLab
Google U.S Patents CEDI/ADI DB AnimAlt-ZEBET SEFREC DaNa
JAPIO CHE TDD Animal
Research.info
TSAR Good Nano Guide
PATDPAFULL EAFUS Atlases-Pathology
Images
3R JRC NMs Repository
SCRIPDB EWAG-BBD AnimalTFDB US EPA Physiological
parameters-PBPK
NANoREG-
eNanoMapper
SureChemBL Exposome Bgee VLN NHECD
USPTO ECHA Summaries Cellosaurus ZFIN Nano Database
WIPO ECODRUG Cefic LRI AMBIT Nano Safety DB
enviPath CEFIC LRI CEMAS Nano techn standards
FDA PAFA DBs CCLE Nanowerk
heatDB CellLineNavigator Nanodic.com
Haz-Map DB-ALM Nano
HSDB EVA NM registry
HCIS Eagle-i NIL
Household Products DB EUROECOTOX Db
of bioassays
NanoHub
HPVIS EMMA NCL
(Continued)
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TABLE 3 | Continued
Patents (9) Environmental
exposure (30)
Animal alternative methods
(39)
Nanomaterials toxicity (22)
IRIS FCS-free Database Nanosafety Cluster
IARC Humane endpoints NECID
iPiE DB Inventory of 3Rs
Kno Sources
Nano data
LINCS IMPC Stat Nano
LactMed ICLAC Smart Nano Tox
OECD-QSAR Interspecies Db
PHAROS IMSR
RiskIE IGRhCellID
REM DB KERIS
RITA LifeMap Discovery®,
Cells & Tiss
TEDX Mouse Atlas of
Gene Expression
TRI MPD
US EPA ECOTOX Non neoplastic
Lesion ATLAS
Organ system
heterogeneity DB
(3D structure, melting temperature, and solubility). It also
includes a chemical fingerprint-based method to search for
similar chemicals based on atom-bond connectivity. OCHEM
contains 20,56,039 records for 548 properties (physchem or
ADME related) and structural alerts for endpoints such as
mutagenicity, skin sensitisation, aquatic toxicity, etc.
II. Toxicological Databases
Fifty-seven databases were identified pertaining to
resources providing information on the effects of drugs
or xenobiotics on cells, organs or the whole body12. Data
are available of many different toxicity endpoints such as:
endocrine disruption, mutagenicity, carcinogenicity, skin
sensitisation, teratogenicity, organ-specific toxicity etc.
Data are either derived from in vitro or in vivo studies
or from in silico prediction across multiple species. Of
the databases identified, a noteworthy example is the
US EPA’s Aggregated Computational Toxicology Online
Resource (AcToR) (Judson et al., 2008), covering over
500,000 chemicals. It is the warehouse for many EPA’s
web-based applications such as the Chemistry Dashboard
(over 700,000 chemicals and includes chemical structures,
experimental and predicted physicochemical, and toxicity
data), Toxicity Forecaster (ToxCast) Dashboard (HTS data
on over 9,000 chemicals and information on ∼1,000 assay
endpoints), Endocrine Disruption Screening Program in
the twenty-first century Dashboard, Chemical Product
Category (CPCat), and exposure databases for personal
care products.
12References are included in Supplementary Data Sheet S1, section II.
Other significant toxicological data resources include
the Gene-Tox database from the National Institutes
of Health (NIH) U.S. National Library of Medicine
(NLM) which comprises mutagenicity data for more
than 3,000 chemicals. The RepDose and FeDTex databases
(Bitsch et al., 2008) are useful sources for No Observed
(Adverse) Effect Level (NO(A)EL) or Lowest Observed
(Adverse) Effect Level (LO(A)EL values from repeated
dose studies for reproductive and developmental toxicity
endpoints. RepDose consists of data on >400 chemicals
investigated in 1,018 studies resulting in 6,002 specific
effects. The HESS database (Sakuratani et al., 2013) contains
information on 28 day repeat dose toxicity studies for 289
industrial chemicals in rats and includes additional rat
metabolism datasets and information on ADME in rats
and humans.
The list of databases also includes toxicogenomic related
data sources such as the Comparative Toxicogenomics
Database (CTD) (Davis et al., 2011), Open-TG Gates
(Igarashi et al., 2015), The Data Infrastructure for
Chemical Safety (diXa) (Hendrickx et al., 2015),
Toxygates (Nyström-Persson et al., 2013; Natsume-
Kitatani et al., 2017) etc. Open-TG-GATES stores gene
expression profiles and traditional toxicological data
derived from in vivo (rat) and in vitro (primary rat
hepatocytes, primary human hepatocytes) exposure to
170 compounds at multiple dosages and time points.
Toxygates is the new interactive version of data from
Open-TG-GATES covering 24,011 samples and 170
compounds. The diXa database provides a one stop
resource for toxicogenomics studies with cross-links
to chemical and molecular medicine databases. diXa
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contains data from 34 studies involving 469 compounds
and recently, all the data have been migrated to the
BioStudies (EMBL-EBI) platform (Sarkans et al., 2018).
BioStudies contains biological data or models and links
them to external resources. At the time of writing it
contains 2,552,605 files, 2,824,923 links, four projects, and
1,214,176 studies. CTD is another valuable resource which
includes more than 30.5 million toxicogenomic connections
relating chemicals/drugs, genes/proteins, diseases, taxa,
Gene Ontology (GO) annotations, pathways, and gene
interaction modules.
ChemTunes & ToxGPS consists of in vitro and in vivo
toxicity endpoint specific alerting chemotypes; mechanism
of action (MOA) based QSAR models, weight of evidence
(WoE) outcomes, and ToxGPS datasets. Other organ
specific toxicity databases inlcude: AMED cardiotoxicity
(Sato et al., 2018), LiverTox (Hoofnagle et al., 2013), Liver
Toxicity Knowledge Base (LTKB) (Chen et al., 2011), the
National Center for Toxicological Research liver cancer
database (NCTRIcdb) (Beger et al., 2004) etc. The AMED
cardiotoxicity database contains data on small molecules
that bind to various ion channels and potentially cause
cardiotoxic risk. The data on bioactivities for hERG potassium
channel were collected from ChEMBL, the NIH Chemical
Genomics Center and hERGCentral. They consist of 9,259
hERG inhibitors (IC50 ≤ 10µM) and 279,718 inactive
compounds (IC50 > 10µM). LiverTox is comprehensive
resource on drug induced liver injury caused by prescription
and non-prescription drugs, herbals and dietary supplements
(1000’s of DILI agents). LTKB has been developed by the
US FDA’s National Center for Toxicological Research to
study drug-induced liver injury (DILI). The data are related
to DILI mechanisms, drug metabolism, histopathology,
therapeutic use, targets, side effects, biomarkers etc. DILIrank
consists of 1,036 FDA-approved drugs that are divided
into four classes, Most-DILI-concern drug (192 drugs);
Less-DILI-concern drug (278 drugs), No-DILI-concern
drug (312 drugs), and Ambiguous-DILI-concern drug
(254 drugs). NCTRIcdb contains 999 chemicals classified
as 273 liver carcinogen, 293 other carcinogen, and 304 as
non-carcinogen based on studies of male and female mice
and rats.
The eTOX database was developed by the European eTOX
project, which was a consortium of 13 pharmaceuticals, data
curators, modellers and software developers funded by the EU
Innovative Medicines Initiative (IMI) Joint Undertaking for 7
years (Steger-Hartmann et al., 2009; Cases et al., 2014; Sanz
et al., 2017). The database provides access to data on repeated
dose toxicity and organ specific toxicity studies and contains
models such as like Human outcomes module, Ontobrowser,
eTox Lab, and Limtox. It covers data on 1,947 pharmaceuticals
out of which 483 labelled as confidential. COSMOS (Cronin
et al., 2012) was another EU funded project which aimed
to develop in silico models for the prediction of human
repeated dose toxicity of cosmetic ingredients to optimise
safety without the use of animals by using computational
models. The tools and approaches includes application of
FIGURE 1 | Chart showing the number of databases within each group. DI,
Drug Information; CT, Clinical trials; PV, Pharmacovigilance; PPI,
Protein-protein interactions; Animal Alt, Animal alternatives.
Thresholds of Toxicological Concern (TTC) of cosmetics
related substances. The database includes more than 80,000
chemical records with more than 40,000 unique structures,
12,000 toxicity studies across 27 endpoints for more than
1,600 compounds.
III. ADME Databases
Thirty-eight ADME databases were identified which captured
information on parameters such as area-under-the-plasma
concentration-curve (AUC), maximum concentration
(Cmax), Time to reach maximum concentration (Tmax),
half-life (T1/2), volume of distribution (Vd), clearance
(CL) etc13. These data were determined from in vitro
and in vivo ADME studies involving different species
(mouse, rats, dogs, monkeys) as well as humans in clinical
studies. Pharmapendium (https://pharmapendium.com)
is one of the most widely used commercial database
(Elsevier group) in the pharmaceutical industry. The
database contains information on 4,331 drugs indexed
and fully searchable for more than 1.53 million PK data,
295,000 metabolising enzyme and transporters data,
1.57 million safety data, 1.69 million efficacy data and
115,000 activity data extracted from FDA/ EMA drug
approval documents.
A number of databases are particularly useful for the
retrieval of information on metabolites e.g., XmetDB
(Spjuth et al., 2016), Metrabase (Mak et al., 2015),
and Akos. XMetDB is an open resource for drugs,
xenobiotics and their experimental metabolite data. It
contains 162 observations from 21 scientific papers from
14 journals, covering 117 chemical structures and 95
enzymes. Akos Metabolites (Accelrys) is a restricted
source containing experimental data from in vivo and
13References are included in Supplementary Data Sheet S1, section III.
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in vitro studies for about 20,000 parent compounds,
100,000 transformations, and 50,000 molecules. It
has indexed relevant metabolic paths for structurally
related systems.
Other influential databases for PK properties include the
ADMEdatabase14 which is a proprietary database from Fujitsu
Kyushu Systems (Japan). This provides the latest and most
comprehensive data on interactions of substances with drug
metabolising enzymes and drug transporters that are specific
to humans. It contains enzyme kinetic values (Km, Vmax, Ki,
Kinactivation, IC50, EC50, T1/2) obtained from the literature. A
recent count shows 35,776 substrates, 28,996 inhibitors, 546
activators as well as 12, 617 data for inducers of CYP450
enzymes. For other enzymes 8,608 substrates, 6,109 inhibitors,
229 activators, and 2,220 inducers were included and in the
case of transporters 14,749 substrates, 6,109 inhibitors, 229
activators, and 2,220 inducers were included. The University
of Washington’s licensed databases such as Drug-Interaction
DB (DIDB), e-PK gene, and Organ induced-DDI (OI-DDI)
(Hachad et al., 2010, 2011; Yeung et al., 2015) are also very
useful. DIDB has the largest manually curated collection
of in vitro and in vivo data related to drug interactions
in humans. Additionally, it covers pharmacokinetic profiles
of drugs, QT (i.e., the time between the start of the Q
wave and the end of the T wave in heart’s electrical cycle)
prolongation data, including results of Thorough QT (TQT)
from recent New Drug Application’s (NDAs) clinical trials
data. e-PK gene, is based on pharmacogenomics i.e., providing
in-depth analysis of the impact of genetic variants of enzymes
and transporters on pharmacokinetic responses to drugs
and metabolites.
OI-DDI contains information on pharmacokinetic
drug exposure data for 271 compounds from publicly
available renal and hepatic impairment studies presented
together with the maximum change in drug exposure
from drug interaction inhibition studies. Databases on
transporters include TP-Search (Ozawa et al., 2004) and
UCSF-Trans Portal (Morrissey et al., 2012). TP-Search
enables the user to search the membrane transporters-related
information by substrate/inhibitor/inducers structure or
name, gene expression, functions, drug-drug interactions
involving transporters (Km/Ki) etc. It coveres more than
75-membrane transporters across different tissues in
mice, rats and humans. The University of California,
San Francisco’s UCSF-Trans Portal provides information
on transporter expression, substrates, inhibitors and
potential drug-drug interactions. The localisation of
transporters in different organs e.g., blood-brain barrier,
kidney, liver, placenta, and small intestine is available
with images, notes, references, and expression data where
available. UCSF Pharmacogenetics (Kroetz et al., 2009) is
a restricted knowledge base providing the information on
genetic variants in membrane transporters in ethnically
diverse populations. The complete list of Solute Carrier
14http://www.fujitsu.com/jp/group/kyushu/en/solutions/industry/lifescience/
admedatabase/
Superfamily (SLC) and the ATP Binding Cassette (ABC)
Superfamily are also provided within UCSF. The user
can also access qPCR expression and MicroArray data.
IDAAPM (Legehar et al., 2016) is a very useful and freely
accessible computational resource for modelling (using
KNIME workflows) to provide information on ADME
properties and known adverse effects of FDA approved
drugs taken from FAERS database. It contains information
of about 19,226 FDA approval applications for 31,815
products, 2,505 active ingredients, 1,629 molecular structures,
2.5 million adverse effects, and 36,963 experimental
drug-target bioactivity data. ADMETlab is a recent
addition in this category which is useful to predict 31
ADMET endpoints prediction, systematically evaluate PK
properties and druglikeness as well as performing chemical
similarity searching using different fingerprint methods
(Dong et al., 2018).
IV. Drug Discovery Databases
One hundred and fifty-seven databases were identified
that relate directly to drug discovery including: small
molecule screening, combinatorial chemistry, molecular
affinity, binding, docking, enzyme interaction, activity, gene
expressions, side-effects, disease, pathways, repurposing of
drugs etc15. Some of the pertinent resources on drug
information are DrugBank, DrugCentral, SuperDrug and
the FDA’s Orange Book. DrugBank (Wishart et al., 2008)
is one of the most widely used databases that includes
information on drugs targets, enzymes and transporters. The
version available at time of writing contains 11,874 drug
entries including 2,474 approved small molecule drugs, 1,177
approved biotech (protein/peptide) drugs, 129 nutraceuticals,
and over 5,748 experimental drugs. Additionally, 5,131
drug target/enzyme/transporter/carrier sequences are linked
to these drug entries. DrugCentral (Ursu et al., 2017) is
another drug compendium covering 4,531 active ingredients,
3,807 small molecules, 279 biologics, 445 other compounds,
77,484 FDA drug labels, 34,192 prescription only drug
labels, 43,292 OTC drug labels, and 97,271 pharmaceutical
formulations with FDA drug labels. The web server for Drug
Central also aids in finding the drug gene signature profile
similarity without linking to other resources. SuperDrug
(Goede et al., 2005) contains 4,605 small molecules, 3,993
Biologicals and 612 other drugs, 4,253 ATC codes, 736,562
3D conformers, 223,860 drug products, 3,006 confirmed
biological targets, 1,450 predicted biological targets, and
109,698 side effects.
A small number of early drug development resources
were also identified; Open Target (Koscielny et al., 2017)
is useful for systematic identification and prioritisation
of targets. At time of writing, it contains 21,149 targets,
2,920,121 associations, and 10,101 diseases. D3R (Gathiaka
et al., 2016; Gaieb et al., 2018) is another resource
containing manually curated datasets on validation
and improvement of methods in computer-aided drug
15References are included in Supplementary Data Sheet S1, section IV.
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design. A single dataset comprises 25 or more congeneric
compounds, 5–10 co-crystal structures, related affinity data
and a number of known inactive compounds. Biovia
MDDR database was jointly developed by BIOVIA
and Clarivate Analytics. It contains 260,000 biologically
relevant compounds and well-defined derivatives. E-LEA3D
(Douguet, 2010) is a source for FDA’s registered molecular
structures −1884 approved between 1939 and 2018 with
a molecular weight ≤2000. The 1,884 different molecular
structures includes structures of enantiomers and of active
metabolites. This resource is dedicated to pharmacology
(molecular structures, PK, Pharmacodynamics (PD) and
registration data.
Databases useful for exploring binding affinity to targets
are also included in Table 3. BindingDB (Gilson et al.,
2016) is an open resource of measured binding affinities,
focusing on the interactions of protein considered to
be drug-targets with small, drug like- molecules and
it contains 1,454,892 binding data, for 7,082 protein
targets, and 652,068 small molecules. AffinDB (Block
et al., 2006) is a database of affinity data for structurally
resolved protein-ligand complexes from the Protein
Data Bank (PDB) and it contains 748 affinity data
out of which 474 were covered from PDB. Brenda
is a widely used resource for enzymes information
including ∼3 million data points from 83,000 enzymes,
137,000 literature references, and a total of 206,000
enzyme ligands providing functional and structural data
(Placzek et al., 2017).
GPCR-LIgand DAtabase (GLIDA) (Okuno et al., 2006)
is a G protein-coupled receptor (GPCR)-related chemical
genomic database that is primarily focused on the correlation
of information between GPCRs and their ligands. It contains
3,738 GPCR-related entries (links to Entrez Gene, GPCRDB,
UniProt, IUPHAR, KEGG) for 649 ligand entries. For docking
purposes Computed Ligand Binding Energy (CLIBE) (Chen
et al., 2002) and CREDO (Schreyer and Blundell, 2013) are
useful. CLIBE is a database developed by National University
of Singapore and useful for the analysis of Drug Binding
Competitiveness. It contains 67,184 entries for ligand binding
energy, in which there are 5,978 distinctive ligands and
2,258 distinctive receptors. In contrast CREDO stores the
interactions between all molecules inside macromolecular
complexes from the Protein Data Bank (PDB). These
molecules include proteins, nucleic acids, carbohydrates as
well as small molecules. CREDO has implemented 13,
different interaction types such as hydrogen bonds, halogen
bonds, carbonyl interactions, and others. Other resources
noted are Target Central Resource Database (TCRD), Pharos
(Nguyen et al., 2017), CARLSBAD (Mathias et al., 2013),
GPCR-Ligand Association Database (GLASS), and GPCR-
EXP (Dai et al., 2016). TCRD and Pharos were both
developed by the Illuminating the Druggable Genome
(IDG) program which aimed for collecting and organising
information about the most common protein targets from
four families -GPCRs, kinases, ion channels, and nuclear
receptors. TCRD collates many heterogenous gene/protein
datasets and Pharos is a multi-modal web interface that
represents the data from TCRD. Overall, the database
covers 72 million associations between all mammalian genes
and their attributes collected from 66 open online major
resources. CARLSBAD is an aggregator of many bioactivity
databases such as ChEMBL, IUPHARDb, Psychoactive Drug
Screening program (PDSP) Ki, PubChem, and WOMBAT.
It provides a single normalised bioactivity value (Ki, EC50
etc.) for chemical-protein target pair. It includes data for
9,32,852 activities, 8,90,323 unique structure-target pairs,
3,739 targets, and 1,301 diseases. The GLASS database
is manually curated repository for experimentally-validated
GPCR-ligand interactions. It contains 3,056 GPCR entries
and 335,271 ligand entries. Whereas, GPCR-EXP provides
information on experimental and predicted structures of
GPCR. It covers data for 55 GPCRs, 282 structures across
9 species (from Protein Data Bank), and 1,076 predicted
structures in human genome. Possum (Ito et al., 2012) is
another standalone database for pocket similarity searching
for predicted and experimentally-derived ligand binding sites
covering 5,513,691 known and putative binding sites obtained
from Protein Data Bank.
Allostery is a process of regulation of biological
macromolecule (protein) function induced by binding
of a ligand (small molecule) at an allosteric site (i.e.,
a distinct site other than the active site) in an efficient
way to control the metabolic mechanisms or signal-
transduction pathways and subsequently increasing the
high receptor selectivity and lowering the target-based
toxicity. This concept helped to build the Allosteric
(Shen et al., 2016) database which has compiled 1,788
allosteric target entries, 77,825 allosteric modulator entries,
82,431 interactions, 1,930 allosteric sites, 56 allosteric
pathways, 261 allosteric networks, and 3,350 allosteric
related diseases.
For pain research, there are various databases including
SuperPain (Gohlke et al., 2014) and Pain Genes database
(PGDB) (Lacroix-Fralish et al., 2007). SuperPain is a
database specifically relating to pain-stimulating and pain-
relieving compounds, which bind or potentially bind
or block to ion channels, e.g., those belonging to the
family of Transient Receptor Potential (TRP) channels
(TRPV1, TRPM8, TRPA1), human ether-a-go-go related
gene (hERG), TREK1, P2X, Acid-sensing ion channels
(ASIC) or voltage-gated sodium channels. It contains
data on 8,700 ligands (experimentally identified) and
100,000 putative ligands. PGDB provides analysis of the
published pain-related phenotypes of mutant mice (over 200
different mutants) and covers 430 genes associated with the
pain mechanism.
Oncology is another domain where large datasets have
been produced and compiled in databases such as Cancer
Target Discovery and Development (CTD2) (Aksoy et al.,
2017), CancerResource (Gohlke et al., 2016), canSAR (Tym
et al., 2016), CancerDRD (Kumar et al., 2013), Genomics
of Drug Sensitivity in Cancer (GDSC) database (Yang et al.,
2013) etc. CTD2 is very useful platform for translation
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of high-throughput and high-content genomic and small
molecule data for oncology. It contains 10,828 cancer cell-
line sensitivity profiling data, 18 oncogenomic screening
observations, 156 chemical-genetic interaction mappings,
66 drug-sensitivity screening results, 24 observations based
on reverse phase protein arrays. Whereas, CancerResource
focuses on cancer related drug-target interactions, expression,
and mutation data as well as drug sensitivity data. It
covers data on 48,404 compounds, 3,387 cancer-relevant
protein targets, 90,744 compound-target interactions, 2,037
cell lines, 19,834 genes, 872,658 mutations, 23,016 genes
(expression). CanSAR is another translational platform, which
integrates genomic, protein, pharmacological, drug, and
chemical data with structural biology, protein networks,
and druggability data. CanSAR contains unique data on
20,316 proteins in human, 556,825 in all species, 143,698
3D structures, 400,892 chains, 12,172 cell lines and 1,962,718
unique structures, 2,148 organisms, 6,367,677 data points
from 59,618 studies, and 244,099 clinical trials. Whereas,
CancerDRD is a database of 148 anticancer drugs and their
effectiveness against around 1,000 cancer cell lines. GDSCdb
is a partially open resource containing information on drug
sensitivity in cancer cells and molecular markers of drug
response. It contains data on 75,000 experiments testing
response to 138 anticancer drugs across almost 700 cancer
cell lines.
With the advent of high—throughput in-vitro technologies
to systematically investigate new indications for existing
drugs has led to the development of repurposing databases
for personalized medicines such as RepurposeDB (Shameer
et al., 2018), repoDB (Brown and Patel, 2017), The Drug
Repurposing Hub (DRH) (Corsello et al., 2017), Promiscuous
(Von Eichborn et al., 2011) etc. RepurposeDB contains
information on 253 drugs (74.30%) and protein drugs
(25.29%) and 1,125 diseases. RepoDB another repositioning
database containing information on 1,519 approved drugs,
386 terminated, 199 withdrawn, and 77 suspended drugs.
DRH contains data on 10,147 compound samples, 2,247
protein targets, 6,125 unique compounds, and 663 drug
indications. Promiscuous connects entities such as drugs,
proteins and side effects as well as mapping the relationships
between them using a network visualisation approach.
To date, data are available for 10,208,308 proteins,
25,170 drugs and drug like compounds, and 23,702
drug-target interactions.
V. Drug Information, Clinical Trials, and
Pharmacovigilance Databases
One hundred and sixteen up-to-date resources on drug
information (medication content, packaging inserts dosing),
drug safety (side-effects), clinical trials information,
and pharmacovigilance are listed that are relevant for
patients, researchers, pharmacists, or prescribers16. Of
these DailyMed17 is the official provider of Food and
16References are included in Supplementary Data Sheet S1 section V.
17https://dailymed.nlm.nih.gov/dailymed/
Drug Administration (FDA) label information (package
inserts) and has information for 98,961 drug listings as
submitted to the FDA. Medicines Complete18 is another
resource for authoritative information to support clinical
and drug research decisions; it includes publications such
as British National Formulary (BNF), BNF for children,
Martindale, Stockley’s Drug Interactions, Martindale’s
Adverse Drug reactions, Drug Administration via Enteral
Feeding Tubes, AHFS Drug Information, Clarke’s Analysis
of Drugs and Poisons, Dale and Appelbe’s Pharmacy and
Medicines Law, Dietary Supplements, Drugs in Pregnancy
and Lactation, Handbook on Injectable Drugs, Herbal
Medicines, Injectable Drugs Guide, Kucer’s the use of
Antibiotics, Pediatric Injectable Drugs, Pharmaceutical
Excipients, Stockley’s Herbal Medicines Interactions, The
Green Guide (rules and guidance for the pharmaceutical
distributors) and the Orange Guide (rules and guidance
for the pharmaceutical Manufacturers and distributors).
It covers 600,000 plus pages of evidence-based drug
information, 200 plus countries access MedicinesComplete
and it has 3.7 million users. MedlinePlus19 is a general
public education related resource, developed by The
National Library of Medicine (NLM), a part of the US
National Institutes of Health. It contains information
on diseases, conditions, and wellness issues over
1,000 topics.
There are a few relevant databases related to
pharmacovigilance listed in this review such as Side Effect
Resource (SIDER) 4.1 (Kuhn et al., 2016), FDA Adverse
Event Reporting System (FAERS) (Fang et al., 2014), Vigibase
(Lindquist, 2008), and EudraVigilance (Postigo et al., 2018).
SIDER 4.1 contains information (extracted from public
documents and package inserts) on marketed medicines and
their recorded adverse drug reactions; presently it covers data
on 1,430 drugs, 5,868 side effects, 139,756 drug-side effects
pairs; 39.9% of drug-side effect pairs have corresponding
frequency of effect information. Another adverse event related
database is FAERS (Fang et al., 2014) which contains adverse
event reports, medication error reports, and product quality
complaints resulting in adverse events that were submitted
to FDA (from Jan 2004 and presently updated quarterly). It
contains 14,160,191 total reports, 8,072,400 serious reports
(excluding death) and 1,420,885 death reports. Vigibase
(Lindquist, 2008) is a unique World Health Organisation
(WHO) global database of individual case safety reports
(ICSRs), it is linked to medical and drug classifications,
including terminologies such as WHO Adverse Reaction
Terminology (ART), Medical Dictionary for Regulatory
Activities (MedDRA) (Morley, 2014), WHO International
Statistical Classification of Diseases (ICD), the medicinal
products dictionary, and WHODrug. It holds over 16 million
anonymised reports of suspected adverse effects of medicines
suffered by patients. EudraVigilance (Postigo et al., 2018) is
the European database of Suspected Adverse Reaction reports
18https://about.medicinescomplete.com/
19https://medlineplus.gov/
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by the EuropeanMedical Agency (EMA). MedDRA provides a
single standardised international medical terminology, which
can be used for regulatory communication and evaluation
of data pertaining to medicinal products for human use. It
supports ICH electronic communication within the ICH’s
Electronic Common Technical Document (eCTD) and the
E2B Individual Case Safety Report. There are five levels
to the MedDRA hierarchy, at the most specific level it is
“Lowest Level Terms” (LLTs), >70,000 terms (e.g., feeling
queasy), “Preferred Term” (e.g., nausea), “High Level term”
(e.g., nausea and vomiting symptoms), “High Level group
term” (GIT signs and symptoms), and “System Organ
Class” (e.g., GIT disorders). ICD-1020 contains guidelines
for systematic recording, coding, analysis, interpretation,
and comparison of mortality-morbidity data collected in
different countries. ClinicalTrials.gov (Zarin et al., 2011) is
a database of privately and publicly funded clinical studies
conducted throughout the world. It is a resource provided
by the US NLM and the user can explore 288,732 research
studies in all the 50 states and in 205 countries. Information
on clinical studies (summary and protocols) are updated by
the sponsor or principal investigator of the clinical study. The
European Clinical Trials Database21 (EudraCT) is developed
and maintained by the European Medicines Agency. The
European Union Clinical Trials Register covers 33,526 clinical
trials with a EudraCT protocol, of which 5,428 are clinical
trials conducted with subjects 18 years old. The register
also displays information on 18,700 older (12–18 years)
pediatric trials.
Ontology driven databases have also emerged recently,
as these can help map other databases, this listing therefore
includes resources such as the Medical Subjects Headings
(MeSH) (Nelson et al., 2001), National Drug File- Reference
Terminology (NDF-RT) (Pathak and Chute, 2010), Unified
Medical Language System (UMLS) (Humphreys et al.,
1998) and The Systematized Nomenclature of Medicine-
Clinical Terms (SNOMED-CT) (Bhattacharyya, 2016).
MeSH database provides controlled vocabulary thesaurus for
medical subjects and it includes medical terms (headings,
subheadings, supplementary concept records, publication
types) for indexing articles for PubMed. MeSH contains
∼26,000 terms and is updated annually. NDF-RT is
developed by the U.S. Department of Veterans Affairs,
Veterans Health Administration (VHA). It organises drug
list into formal representation. The categories of NDF
hierarchical drug classifications are Cellular or Molecular
Interactions (MoA), Chemical Ingredients, Clinical Kinetics
(PK), Diseases, Manifestations or Physiologic States, Dose
Forms, Pharmaceutical Preparations, Physiological Effects,
Therapeutic Categories, and VA Drug Interactions. NDF-
RT is updated monthly as a part of RxNorm. UMLS is a
repository of biomedical vocabularies developed by US
NLM. It has three components- The Metathesaurus R© of
20https://icd.who.int/browse10/2016/en#/X
21https://eudract.ema.europa.eu/
inter-related medical concepts, Semantic networks (high-
level categories) and the SPECIALIST Lexicon which
“contains syntactic, morphological, and orthographic
information for biomedical and common words in the
English language”. The UMLS covers 2 milion names for
some 900,000 concepts from >60 families of biomedical
vocabularies, as well as 12 million relations among these
concepts. SNOMED-CT is a database on structured clinical
vocabulary for use in an electronic health record. It provides
a standardised way to represent clinical phrases captured by
the clinician and enables automatic interpretation of these.
It is multinational and multilingual, and it contains 340,659
active concepts.
VI. Biological Databases
There are 268 biological databases. This category of databases
refers to the resources containing information on enzymes
(kinase, GPCRs, CYPs etc.) antibodies, receptors, tissue
specific gene expressions/ regulations, annotated protein-
peptide sequences, genetic and metabolic signaling, RNA,
lipids, immune-system components etc22. Enzyme related
information are provided in databases such as Enzyme
Portal (Alcántara et al., 2013), GPCRdb (Pándy-Szekeres
et al., 2018), International Union of Basic and Clinical
Pharmacology- British Pharmacological Society (IUPHAR-
BPS) Guide to Pharmacology (Hay et al., 2018), Integrated
relational Enzyme database (IntEnz) (Fleischmann et al.,
2004), Kinase.com, Kinweb etc. Enzyme Portal is a
comprehensive database by EMBL-EBI and it contains
information on enzymes, such as small-molecule chemistry,
biochemical pathways, and drug compounds. It provides
a summary of information from UniProt Knowledgebase,
Protein Databank in Europe (PDBe), Rhea (enzyme-
catalysed reactions), Reactome (biochemical pathways),
IntEnz (enzyme nomenclature information), ChEBI and
ChEMBL (small molecule chemistry and bioactivity),
MACiE (reaction mechanism), and the Experimental
Factor Ontology (EFO). GPCRdb contains data on GPCR
structures and large collections of receptor mutants. The
database covers data on 15,090 proteins, 418 human proteins,
3,547 species, 270 experimental structures, 184 refined
structures, 144,860 ligands, 34,353 mutants, and 12,300
ligand interactions. IUPHAR/BPS Guide to Pharmacology
provides data on molecular interactions between target
and ligands from selected papers in pharmacology and
drug discovery since 2003. It covers 2,880 total number of
targets, 9,405 ligands and 1,383 approved drugs with clinical
use summary.
For DNA, RNA, and gene datasets, there are number of
databases available such as GenBank (Benson et al., 2013),
Gene Expression Ontology (GEO) (Barrett et al., 2013),
The Genotype-Tissue Expression (GTEx) portal (Stranger
et al., 2017), Hugo gene Nomenclature Committee (HGNC)
(Gray et al., 2016), Human Protein Atlas (HPA) (Uhlen
et al., 2010), Encyclopedia of DNA element (ENCODE)
22References are included in Supplementary Data Sheet S1, section VI.
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(The ENCODE Project Consortium, 2011), Ensembl, TP-53
(Leroy et al., 2013), European Nucleotide Archive (ENA)
(Silvester et al., 2018), European Genome-phenome Archive
(EGA) (Lappalainen et al., 2015) etc. GenBank is the
NIH genetic sequence database, an annotated collection of
all publicly available DNA sequences. It contains publicly
available nucleotide sequences for almost 260,000 formally
described species. GEO is a portal for the application
ontology for the domain of gene expression. Its metrics
indicates 166,254 classes, 157,102 individuals, 12 properties
and 50,996 maximum number of children. GTEx database
is a great resource to study tissue-specific gene expression
and regulation. The 11,688 samples were collected from
53 non-diseased tissue sites and 714 donors. HGNC is the
worldwide authority that assigns standardised nomenclature
to human genes. It approves both a short-form abbreviation
known as a gene symbol and a longer and more descriptive
name. HPA database consists of three parts; the Tissue
Atlas provides the distribution of proteins across all major
tissues and organs in the human body, the Cell Atlas
provides the subcellular localisation of proteins in single
cells and the Pathology Atlas shows the impact of protein
levels for survival of patients with cancer. In the latest
version, the Human Protein Atlas contains more than
26,000 antibodies, targeting proteins from almost 17,000
human genes.
The ENCODE consortium is supported by the National
Human Genome Research Institute (NHGRI) and it
has systematically mapped regions of transcription,
transcription factor association, chromatin structure,
and histone modification. The ENCODE portal contains over
13,000 datasets available through the portal from human,
mouse, Drosophila and Caenorhabditis elegans assayed
under a variety of different physiological conditions. The
Ensembl database provides a bioinformatics framework to
organise biology around the sequences of large genomes.
Ensembl annotate genes, computes multiple alignments,
predicts regulatory function, and collects disease data.
TP-53 (tumor protein or cellular tumor antigen p53) is a
database related to the structure of the TP53 gene, TP53
isoforms, mutation nomenclature, and the sequence of
more than 5,000 tumor samples from 12 cancer types. The
current release contains 80,400 tumors, 6,870 different
TP53 variants. The ENA (EMBL-EBI) is a comprehensive
resource on world’s nucleotide sequencing information,
raw sequencing data, sequence assembly information
and functional annotation. It contains information on
2042.8 millions of nucleotide sequences and 5021.7
billions bases. The EGA contains data on personally
identifiable genetic and phenotypic data resulting from
biomedical research projects. In the entire EGA there is
a total of 1,706 studies (960 cancer, 134 cardiovascular,
39 infectious, 59 inflammatory, 63 neurological, and
362 others).
VII. Protein-Protein Interaction Databases
To understand the relationships between proteins, protein-
protein (PP) interaction studies are required and this has
led to the creation of many valuable databases to catalog
and annotate these PP interactions. Fifty-four databases are
listed in Table 323. Some of the most valuable resources are
Agile Protein Interactomes Data server (APID) (Alonso-
Lopez et al., 2016), The Biological General Repository
for Interaction Datasets (BioGRID) (Chatr-Aryamontri
et al., 2015), CancerNet (Meng et al., 2015), CompPPI
(Veres et al., 2015), The Database of Interacting Proteins
(DIP) (Xenarios et al., 2000), Database of Macromolecular
Interactions (DOMMINO) (Kuang et al., 2012), gpDB
(Theodoropoulou et al., 2008), GWIDD (Kundrotas et al.,
2012), Human Interactome Project (HIP) (Rual et al., 2005),
Innatedb (Breuer et al., 2013), IntAct (Hermjakob et al.,
2004), and Manually Annotated Targets and Drugs Online
Resource (MATADOR) (Gunther et al., 2008). Possibly
most relevant is APID which is a collection of protein
interactomes for more than 400 organisms based in the
integration of known experimentally validated protein-
protein physical interactions (PPIs). It covers 375,389
interactions and 29,891 interacting proteins. BioGRID
contains genetic and protein interactions curated from
the primary biomedical literature for all major model
organism species and humans. It contains 1,607,037 proteins
and genetic interactions, 28,093 chemical associations
and 726,378 post translational modifications (PMT) from
major model organism species. CancerNet is a human
cancer-specific miRNA-target interactions, protein-protein
interactions (PPIs) and functionally synergistic miRNA
pairs database. It contains interactions across 33 types of
human cancers and also PPI information across 33 main
normal tissues and cell types. CompPPI (Veres et al., 2015)
stands for compartmentalised PPI database, which provides
qualitative information on the interactions, proteins and
their localizations for PPI network analysis. For human
species, it covers 94,488 proteins, 266,306 localisations and
1,311,184 interactions.
The DIP database catalogues experimentally determined
interactions between proteins. It combines information from
a variety of sources to create a single, consistent set of protein-
protein interactions. It contains 28,826 proteins, covering
834 organisms, 81,762 interactions (lists protein pairs that
are known to interact with each other), results from 81,913
distinct experiments describing an interaction and 8,233
data sources. DOMMINO (Kuang et al., 2012) is based
on macromolecular interactions and at time of writing it
covers more than 407,000 binary interactions. The gpDB
(Theodoropoulou et al., 2008) is a resource for GPCRs,
G-proteins, Effectors (molecules) and their interactions. It
contains 391 entries relating to G-proteins, 2,738 GPCRs
entries and 1,390 effectors with data for 469 species. GWIDD
(Kundrotas et al., 2012) is an integrated resource for structural
studies of protein-protein interactions on a genome-wide
scale covering 126,897 binary interactions, involving 43,976
proteins from 771 different organisms. HIP (Rual et al., 2005)
is an open resource on human protein-protein interactome
network and covers 11,999 proteins and 74,820 Interactions.
23References are included in Supplementary Data Sheet S1, section VII.
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Innatedb (Breuer et al., 2013) is a knowledge resource
for innate immunity interactions and pathways and covers
27,172 curated interactions and 9,460 curated genes. IntAct
(Hermjakob et al., 2004) is a common curation platform for
11 molecular interaction databases and containing 572,063
interactions and 107,900 interactors. MATADOR (Gunther
et al., 2008) is a unique resource for protein-chemical
interactions and it covers 775 drugs and their interactions
with proteins.
VIII. Omics
This category is related to the resources containing datasets
derived from in vitro highthroughput screening (HTS)
studies covering all the datasets in metabolomics, proteomics,
genomics, transcriptomics, and fluxomics. This category
contains 60 databases24. A key example is ArrayExpress
(Parkinson et al., 2007) which is an archive of functional
genomics data stores data from high-throughput functional
genomics experiments and covers 71,472 experiments and
2,311,652 bio assays. It accepts all functional genomics data
generated from micoarray or next-generation sequencing
(NGS) platforms. The Biochemical Genetic and Genomic
(BiGG) database (King et al., 2016) is a resource based on
more than 70 genome-scale metabolic networks. Genes in the
BiGG models are mapped to NCBI genome annotations, and
metabolites are linked to many external databases (KEGG,
PubChem, and many more). BioSample (Barrett et al., 2012)
contains descriptive information about almost 2 million
records (a cell line, a tissue biopsy etc.) encompassing 18,000
species whereas Biostudies is a repository for descriptions
of biological studies from large projects (e.g., Blueprint,
Europe PubMed Central, Eurocan Platform, and diXa data
warehouse) and individuals. Currently it covers 2,552,610
files, 2,824,924 links, 4 projects, and 1,214,179 studies. Cancer
GenomicHub is a repository that enables data sharing across
cancer genomic studies in support of precision medicine. This
database is derived from 40 projects, 61 primary sites, 32,555
cases, 356,381 files, 22,147 genes, and 3,142,246 mutations
datasets. The chronic kidney disease database (CKDdb)
(Singh et al., 2012) contains multi-omic studies (microRNA,
genomics, peptidomics, proteomics, and metabolomics) of
chronic kidney disease (CKD), disease-related and diseases
leading to this trait. Presently it has differential expression data
from 49,395 molecule entries (redundant), of which 16,885
are unique molecules (non-redundant) from 377 manually
curated studies of 230 publications. Disnor (Lo surdo et al.,
2018), DrugSig (Wu et al., 2017), DisGeNet (Piñero et al.,
2017), Drug Gene Interaction Database (DGIdb) (Griffith
et al., 2013), Online Mendelian Inheritance in Man (OMIM)
(Hamosh et al., 2005) are important resources for exploring
the genes and disease domain. Disnor contains information on
more than 3,700 disease-pathways and linking ∼2,600 disease
genes to diseases. Whereas, DrugSig contains information
on drug induced gene signature for drug repositioning for
24References are included in Supplementary Data Sheet S1, section VIII.
more than 1,300 drugs. DisGeNet contains 561,119 gene-
disease associations (GDAs), between 17,074 genes and 20,370
diseases, disorders, traits, and clinical or abnormal human
phenotypes. DGIdb contains over 40,000 genes and 10,000
drugs involved in over 15,000 drug-gene interactions or
belonging to one of 39 potentially druggable gene categories
whereas OMIM is a widely used, an Online Catalog of
Human Genes and Genetic Disorders and traits. Omics
Discovery Index (Omics DI) (Perez-Riverol et al., 2017)
is a great resource containing heterogeneous omics data
covering 452,800 datasets, 65,200 species, 308,300 genomics,
1,600 tissues, 124,400 transcriptomics, 19 repositories, and
7,300 multiomics datasets. The HumanMetabolome Database
(HMDB) (Wishart et al., 2017) is a widely used database on
small molecule metabolites found in the human body covering
114,110 metabolites entries (both water and lipid soluble) and
linked to 5,702 protein sequences. Another useful resource on
metabolites is the Metabolomics workbench (Sud et al., 2016),
it contains structures and annotations of biologically relevant
metabolites (>61,000 entries). MetaMapTox (Fabian et al.,
2016) is a licensed resource for metabolite profiles from rat
plasma and comprehensive pharmacological and toxicological
data. Overall, it covers 25 specific and predictive toxicological
mode of action (MoA) in eleven different target organs.
RefSeq (Nasko et al., 2018) is a comprehensive, integrated,
non-redundant, well-annotated set of sequences, including
genomic DNA, 20,905,608 transcripts, and 100,043,962
proteins, and 73,996 organisms. MetaboLights (Kale et al.,
2016) contains cross-species, cross-technique and covers
metabolite structures and their reference spectra as well
as their biological roles, locations and concentrations, and
experimental data from metabolic experiments. PharmacoDB
(Smirnov et al., 2018) is a cancer pharmacogenomic database
covering 7 datasets, 41 tissues, 1,691 cell lines, 19,933 genes,
759 drugs, and 650,894 experiments. TCGA (Weinstein
et al., 2013) is another resource on cancer genome data
containing an array of molecular alterations underlying 206
cases of adult soft tissue sarcomas. RGED (Zhang et al.,
2014) is a database of gene expression profiles in kidney
disease which covers 55 RNA-sequence data, 5,299 DNA
microarray, 101 cell lines, and 5,253 tissues. Connectivity Map
(Lamb et al., 2006) is a very large genome-scale library of
cellular signatures that catalogues transcriptional responses to
chemical, genetic, and disease perturbation. It contains more
than 1million profiles resulting from perturbations of multiple
cell types.
IX. Pathways-Based Databases
Pathways based toxicity databases are useful in the
development of AOPs. This category contains 38 databases25.
Important pathway based databases include the AOP-wiki
or Wiki Pathways, Effectopedia (Vinken et al., 2017), KEGG
(Kanehisa and Goto, 2000), Pathway commons (Cerami et al.,
2011), Reactome (Croft et al., 2011), PathCards (Belinky et al.,
2015), XTalkDB (Sam et al., 2017) etc. Effectopedia is a part of
25References are included in Supplementary Data Sheet S1, section IX.
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AOP Knowledge Base, which has four platforms–AOP-Wiki,
Effectopedia, AOP Xplorer and Intermediate Effects DB. It
contains 244 AOPs and 1,806 key events. KEGG is a vast
encyclopedia of genes and genomes and classified into many
modules as Pathway, Brite, Module, Orthology, Genome,
Genes, Compound, Glycan, Reaction, Enzyme, Disease,
Drug etc. Pathway Commons is a collection of publicly
available pathway data from multiple organisms covering
4,000 pathways and 1.3M interactions. Reactome is a unique
database, which includes transformations of entities such as
transport from one compartment to another and interaction
to form a complex, as well as the chemical transformations
of classical biochemistry. Its latest version includes 2,244
human pathways, 12,047 reactions, 10,778 proteins, and
1,948 small molecules. PathCards is an integrated database
of human biological pathways and their annotations. In
addition, the human pathways are clustered into SuperPaths
based on gene content similarity. The other DBs such as
Genecards (Safran et al., 2010), MalaCards (Rappaport
et al., 2014), and GeneLoc (Rosen et al., 2003) could be
useful along with PathCard database. Overall, it contains
1,289 SuperPath entries, consolidated from 12 sources.
XTalkDB is based on scientific literature supporting crosstalk
between pairs of signaling pathways and presently contains
650 curated pathway pairs, 345 crosstalking pathway pairs,
1697-curated publications.
X. Patent Databases
Nine databases were identified relating to patents26; these
are of paramount importance in drug discovery, drug
formulations, production, and marketing of new molecules
(Heifets and Jurisica, 2012; Papadatos et al., 2016). In
addition, databases which contained information on chemical
structure, synthesis, in vitro or in vivo mode of actions
etc. are included. Derwent Discovery27 covers patents
from 32 countries and contains 141.3 million backward
citations (cited), 148.9 million forward citations (citing),
34.5 million literature citations. Whereas, the European
Patent Office (EPO)28 provides free access to over 100
million patent documents. SureChEMBL (Papadatos et al.,
2016) contains compounds chemistry extracted from the
full text, images and attachments of patent documents from
major patent authorities (WIPO, USPTO and EPO). It
contains 17 million compounds extracted from 14 million
patent documents.
XI. Environmental Databases
There are 30 databases with information on the effects of
chemcials to the environment and non-human species29.
This category of databases are related to potential, hazardous,
or toxic chemicals, which are ubiquitous in nature and
are present in air, water, food, soil, dust consumer goods,
26References are included in Supplementary Data Sheet S1, section X.
27https://clarivate.com/products/derwent-world-patents-index/
28https://www.epo.org/index.html
29References are included in Supplementary Data Sheet S1, section XI.
and are detected in the human body. The Agency for
Toxic Substances and Disease Registry (ATSDR) DB
(Johnson, 1995) is maintained by the U.S. Department
of Health and Health Services, useful in protecting
the communities from harmful health effects related to
exposure to natural and man-made hazardous substances.
It contains A-Z chemical lists of 275 substances and
their toxicological profiles. The Hazardous Substances
Data Bank (HSDB) (Fonger, 1995) is another toxicology
databank from TOXNET and it covers 5,800 records on
human exposure, industrial hygiene, emergency handling
procedures, environmental fate, regulatory requirements
etc. CEDI30 and ADI DB (Sugita et al., 2006) are related to
Cumulative Estimated Daily Intakes (CEDIs) and Acceptable
Daily Intakes (ADIs) for a large number of food contact
substances. The database contains information on over
3,000 substances.
The U.S. EPA’s ECOTOX database31 provides information
on adverse effects of single chemical stressors to ecologically
relevant aquatic and terrestrial species. It contains data relating
to 11,655 chemicals, 12,630 species obtained from 48,064
references and 919,123 individual results. The Integrated Risk
Information System (IRIS) is another product from U.S. EPA
and it contains basic information about the risk assessment for
groups of chemicals or complex mixtures. It provides toxicity
values for health effects resulting from chronic exposure
to more than 500 chemicals: Reference Concentration
(RfC), Reference Dose (RfD), Cancer descriptors, Oral slope
factor (the slope factor used with administered doses to
estimate the probability of increased cancer incidence over a
lifetime) etc.
The European Centre for Ecotoxicology and Toxicology
of Chemicals- Human Exposure Assessment Tools Database
(ECETOC-heatDB) is a public directory of exposure data
sources as well as available tools for exposure. Haz-
Map R© is a relational database of hazardous chemicals and
occupational diseases. The database currently contains 12,086
chemical and biological agents, 240 diseases, 121 findings
(signs and symptoms), hazard specific to 261 jobs, 243
job tasks, 54 industrial processes, 624 industries, and 27
non-occupational activities. LINCS (Liu et al., 2015) is a
standalone library of molecular signatures describing how
different types of cells respond to a variety of chemicals
called “perbutagens.” At time of writing, this comprised 391
datasets covering 41,847 small molecules, 1,127 cell types
derived from different organs, 978 genes, 1469 proteins/155
peptide probes, and 8 antibodies. Another noteworthy
resource is the OECD QSAR Toolbox, a tool for grouping
of chemicals for read-across that can be applied to data
gap filling. It contains 69 profilers (e.g., DNA binding,
protein binding, acute aquatic toxicity, carcinogenicity alerts,
in vitro and in vivo mutagenicity alerts, keratinocyte gene
expression, HESS profiler etc.) and 55 databases [CPDB,
30https://www.fda.gov/Food/IngredientsPackagingLabeling/PackagingFCS/
CEDI/default.htm
31https://cfpub.epa.gov/ecotox/
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DART, Ecotox, RepDose, ToxcastDB, ZEBET, developmental
toxicity database (CAESAR), EFSA Food Tox Hazard
Database, EFSA Genotoxicity, REACH bioaccumulation data,
GARDskin database etc.] with over 70,000 chemicals and
2,116,700 data points.
XII. Animal Alternative Databases
Thirty-nine Animal alternative databases were identified
relating to data resources32, which assist researchers in
complying with the 3Rs philosophy of reduction, refinement
and replacement of animal use by. Examples of these databases
include: Bibliography on Alternatives to Animal Testing
(ALTBIB) (Liebsch et al., 2011) that provides citations from
year 2000 to present year. AnimAlt-ZEBET (Grune et al.,
2000) is another unique resource, which includes high quality,
scientifically recognised 149 alternative methods to standard
animal tests in the field of toxicology and pharmacology
as well as fundamental research. Bgee provides information
on gene expression patterns in 29 animal species, produced
from multiple data types such as RNA-Seq, Affymetrix
etc. (Bastian et al., 2019) The EURL ECVAM Database
service on Alternative Methods to animal experimentation
(DB-ALM)33 developed by the EU Joint Research Centre
(JRC) provides evaluated information on development and
applications of advanced and alternative methods to animal
experimentation in biomedical sciences and toxicology, both
in research and for regulatory purposes. The Tracking System
for Alternative Methods toward Regulatory Acceptance
(TSAR) database34 is useful in identifying alternative non-
animal methods that have been proposed for regulatory
safety or efficacy testing of chemicals or biological agents
such as vaccines. For in vitro related DBs, Cellosaurus35
knowledge resource on cell lines is a good example
covering 109,135 cell lines (81,617 human, 19,451 mouse,
1,952 rat).
The Fetal Calf Serum Free database (FCS-Free Db)36
provides a list of FCS-free media available for specific cell
lines or cell types. The International Cell Line Authentication
Committee (ICLAC)37 provides lists of 4,000 cell lines that
are currently known to be cross-contaminated or otherwise
misidentified or arising from the work of laboratories
and cell line repositories worldwide. LifeMap Discovery R©,
Cells and Tissues Database (Edgar et al., 2013) covers
data in embryonic development, stem cell differentiation,
regenerative medicine, and in vivo and in vitro gene
expression data curated from scientific literature and HTS
data sources. Non-neoplastic Lesion ATLAS (Schmidt,
2014) is a very useful guide for standardising terminology
in toxicological pathology for rodents. Another useful
database is Organ System Heterogeneity DB, which provides
32References are included in Supplementary Data Sheet S1, section XII.
33https://ecvam-dbalm.jrc.ec.europa.eu/
34https://tsar.jrc.ec.europa.eu/
35https://web.expasy.org/cellosaurus/
36https://fcs-free.org/
37http://iclac.org/
information on the phenotypic heterogeneity of diseases,
drugs and mutations in mouse genes on 26 different organ
systems defined in using MedDRA ontology at the SOC
(System Organ Class) level. The Interspecies database
which helps to select the most appropriate animal model,
which is essential for efficient extrapolation of animal data
to humans or other animals. It provides information on
physiological, anatomical, and biochemical parameters
across species.
XIII. Nanomaterial Toxicity Databases
22 databases exist that contain information on the properties
and toxicity of nanomaterials or their products38. The
databases include NANoREG—eNanoMapper database
(Jeliazkova et al., 2015), developed by EU FP7 eNanoMapper
project and it contains toxicological data for the nanomaterials
collected by 85 partners across the world. NHECD (Maimon
and Browarnik, 2010) is another free database with its
main objectives to study the impact of nanoparticles on
health, safety, and environment. It has curated a large and
developing collection of published data on environmental
and health effects following exposure to nanomaterials. The
EU Nano Safety Cluster is an open platform containing
the Horizon 2020 projects (e.g., SmartNanoTox, NanoReg
II, PATROLS etc.) addressing the safety of materials and
technologies enabled by the use of nanoparticles. The
Nano- Database39 is developed by DTU Environment,
the Danish Ecological Council and Danish Consumer
Council. It consists of assessments of the nanomaterials
used in various consumer products and NanoRisk Cat
categorization. There are nearly 3,036 products in this
database. The Nano database40 created by Nature and
Springer. The database contains data on nanomaterials,
methods of production, and nano-instruments. The data
have been curated from articles, patents, and other scientific
sources. StatNano41 is another comprehensive database on
7,000 nanotechnology products. It also contains analytical
reports on the trend of nanotechnology influence on different
industries, nanostructures and nano materials.
DISCUSSION
With the advances in HTS, chemical synthesis, and biological
screening (activity, potency, safety profiles), the number of
commercially or publicly available databases containing this
information has expanded rapidly. This review has resulted
in the compilation of nearly 1,000 databases which have been
systematically grouped and classified based on content and
potential applications. The databases listed cover many areas
including: chemical information, drug screening, toxicity
(including toxicity of nanomaterials), ADME, binding, docking,
clinical trials, pharmacovigilance, genes, enzymes, interactions,
38References are included in Supplementary Data Sheet S1, section XIII.
39http://nanodb.dk/en/
40https://nano.nature.com/
41https://statnano.com/
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omics, pathways, patent information, environmental exposure,
and databases providing information on alternatives
to animals.
Criteria for characterising databases were considered as
summarised in Table 2. The essential criteria were accessibility,
relevance of endpoints, chemical identifiers, acceptable ontology,
appropriate (or readily convertible) units, ease of data download
in different formats and interoperability. Desirable criteria
includes access to metadata (study proptocols and statistics),
an assessment of the data quality, ease of use, relevant data
description (e.g., classification codes) and currency of data.
Ontology based databases were also listed which are useful to
integrate the semantic data. For efficient database integration,
flexible, and robust APIs are essential to support large datasets.
One of the significant bottlenecks in database integration is
identifying unique data types to ascertain the overlap between
data in two or more databases.
Several factors need to be considered when using the
increasing number of data resources for predictive toxicology
and other purposes. A very important aspect is the accuracy
and uniformity of the identity of the chemical and its chemical
structure. Uniform chemical structures are often not included
in databases and, on occasions, may even be incorrect. Further
complications may arise as different salt forms, enantiomers,
or isotopes may not be differentiated. One means to assist in
the confirmation of the the identity of chemicals is to include
a machine–readable representation of the chemical structure
(e.g., SMILES, InChI, SDF), along with the key identifiers,
such as InChIkeys. Linked to the need for correct chemical
identifiers is the prerequisite for high quality chemical structures
to ensure the accuracy, completeness and consistency of the
information stored in databases. The process of checking
the accuracy, or otherwise, of chemical structures can be
undertaken using the InChIs and SMILES representations
(amongst others). This helps to avoid incorrect structures by
detecting duplicate chemical structures, mismatches between
structures, different stereoisomer/tautomer forms, mesomeric
effects, hypervalency (atom centre displays valency outside
its normal value), and numerous other issues relating to
chemical bonds and inorganic elements (Fourches et al., 2010).
To standardise and normalise the databases, methods such
as chemical structure standardisation (removal of mixtures,
inorganics, organometallics, salts, solvents and fragments;
normalisation of specific chemotypes/metabolites; treatment
of tautomeric forms; removal of duplicates), assigning the
unique IDs for the samples, de-duplication of the experimental
datasets, validation of omic technologies (Sauer et al., 2017) and
avoiding multiple measurements for the same parameters etc.
should be applied. One critical step in the standardisation or
normalisation procedure is to compile datasets with uniform
unit values for a particular parameter derived from heterogonous
resources. Uniform units are required to compare and analyse
multiple datasets. For example, whilst many data exist for
pharmacokinetics properties, there is no or little consistency even
in the key parameters, often with discrepancies or differences
in units/measured values. However, taking an essential propery
such as intrinsic clearance (Clint) measured in vitro for enzymes
as an example, the variability in units can be corrected and
normalised to mL/min/g of protein.
To check the accuracy, completeness, and consistency of the
databases, a number of qualitative and quantitative methods can
be used. For accuracy, the quality of the data in the databases, i.e.,
chemical structures, can be confirmed against CAS numbers by
cross-referencing with chemical name. The records for the data
generated should be mentioned on the website as well as details
and results of the validation along with the statistics (number
of compounds covered, version number). Consistency can be
checked for the data in different version updates of the database,
however, this information is seldom provided. Metadata i.e., a
representation of supporting data in different formats, are not
systematically implemented in databases. Resolving this issue
would assist in mapping datasets to each other and save time in
finding a relevant study. It is also clear that many data resources
contain many of the same data and sources of information.
In addition, many of the data published in journals, books,
or dataset compilations have been merged in single platforms
(e.g., PubChem) which makes searching easier. As such, this has
resulted in a great deal of overlap between existing databases and
potentially the propagation of errors (i.e., an error being carried
forward across data sources due to a lack of manual checking).
However, overlap between the databases is not considered a
major problem and it could be minimised by clearly identifying
the origin of data and using primary sources where possible.
Ontologies help in mapping and data integration by providing
the syntax for describing classes (or concepts), properties
and relationships between classes in the domain of discourse.
Mapping between the schema (organisation of data as a blueprint
of how the database is constructed) and domain ontologies are
an important component for information integration. Whereas,
metadata are data that describe the elements in a dataset (e.g.,
Name of the table, Type of columns, and relationships between
them) and help in importing the dataset files from one resource to
another or consolidate multiple databases into a single database.
For many databases licensing terms and conditions are provided.
Clear license information is crucial so that the end user knows
what can be done with the metadata. Open licenses for databases
encourage access and download of data in a machine-readable
format together with their metadata. Some databases apply the
license to the whole database or some third party datasests.
The end users are recommended to read and understand the
licensing information correctly to know whether the contents
are provided for commercial or educational research purposes
only. The researchers or data owners are also recommended
to publish the metadata under a public domain license to
ensure wide distribution and reuse. Interoperable databases,
i.e., those with a user-friendly, interface, and the capacity for
easy interaction and exchange with the other systems, are
favoured. The choice of a particular API depends on the size
of the database and the programming skills of the developer.
Creating databases with greater interoperability will increase
their utility and potential application in diverse areas. In addition,
database mapping can be defined as the process of identifying
key data sources (web pages, flat files, XML-formatted data,
directly accessible DBs) by using methods such as ontologies,
Frontiers in Pharmacology | www.frontiersin.org 20 June 2019 | Volume 10 | Article 561
Pawar et al. Databases for Computational Toxicology
programming codes, graphical interfaces, and then linking those
relevant databases before merging (integration) into a common
platform or a single database. Mapping of different databases
depends on the technical content and architecture of the
datasets. For better mapping and integration easy access to the
metadata are preferred. The content accessibility provided by
the different databases vary: the majority of databases are open
platform enabling searching of scientific data, some facilitate data
downloading in different formats. Access to some databases is
restricted e.g., commercially available databases.
Looking to the future and potential use of in silico resources,
the integration of databases with in silico tools for predicting the
properties or activities of compounds could be useful for early
decision making in drug discovery and chemical risk assessment.
The computational tools should not be limited to only chemistry
or biology but should be able to link chemistry with activity,
toxicity and the underlying mechanistic information. In other
words, the tools should integrate information on dosimetry,
human exposure (in silico) and in vitro toxicity screening data
to provide a better chemical safety risk assessment.
An enormous variety of databases relating to in silico
toxicology, prediction, and safety assessment are available; other
potential uses of these databases include the identification of
chemically and/or biologically similar chemicals for read-across
purposes. In future development of databases key attributes to
consider include data quality, accessibility, ease of downloading
the data, chemical space coverage, and range of bioactiviy.
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